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Summary Northern analysis of tumour RNA has been used to examine the expression of members of the myf
family of muscle determining genes (myf3, myf4, myf5 and myf6) in a series of 20 rhabdomyosarcomas. A
2.0kb myf3 transcript was observed in 85% of tumours, a 1.8 kb myf4 transcript was detected in 70% of
tumours and a 1.7 kb myf5 transcript was observed in 55% of tumours. Transcription of myf6 occurred in
28% of tumours, but there were several transcript sizes (1.2, 1.5, 2.0 and 3.5 kb) and in some individual
tumours two or more transcripts were observed. Only two rhabdomyosarcomas, one classified as embryonal
and one as pleomorphic, failed to exhibit transcription of members of the myfgene family. We were unable to
detect transcription of myf genes in neuroblastomas, Wilms' tumours, hepatoblastomas, paediatric non-
Hodgkin's lymphoma and leiomyosarcomas. When considered together these observations suggest that expres-
sion of myf genes could provide an extremely useful marker in the diagnosis of rhabdomyosarcoma.
The development of skeletal muscle is a complex process in
which multipotent stem cells initially become committed to
form mononuclear myoblasts. The myoblasts then fuse to
form myotubes which in turn mature into striated muscle.
Recent studies have demonstrated that the transition along
this differentiation pathway may be determined, at least in
part, by a family of trans-acting transcription factors that are
directly involved in controlling the expression of muscle
specific genes. The first genes found to encode muscle deter-
mining factors were the mouse MyoDl gene (Davies et al.,
1987) and the rat myogenin gene (Wright et al., 1989) which
were both isolated by procedures involving subtractive
cDNA hybridisation. Subsequently Braun et al. (1989b, 1990)
isolated two related genes designated myf5 and myf6 from a
human foetal muscle cDNA library and an additional two
genes called myf3 and myf4 (Braun et al., 1989a) that are the
human homologues of, respectively, MyoDI and myogenin.
Each of the four myf genes encodes a highly conserved
basic-helix-loop-helix region that is believed to be responsible
for the binding of myfproteins to enhancer regions in muscle
specific genes. In addition, each gene can convert mouse
fibroblasts into cells with myogenic characteristics and in
analyses of normal tissue all four genes were expressed
exclusively in striated muscle (Braun et al., 1989a,b 1990).
Rhabdomyosarcomas are tumours that show differentiation
towards striated muscle. Conventionally, three main histo-
logical subtypes are recognised (Enzinger & Weiss, 1988).
Most (70-80%) are embryonal rhabdomyosarcomas that fre-
quently have the microscopic appearance of foetal muscle
and vary in morphology from undifferentiated round cell
tumours with few discernible myoblasts to well differentiated
tumours containing a high proportion of myoblasts (Enzinger
& Weiss, 1988). They usually arise in the first and early
second decades of life and account for 6-7% of paediatric
neoplasms. Alveolar rhabdomyosarcomas, which usually
occur during the second and third decades, are composed of
aggregates of poorly differentiated cells that are separated by
bands of dense fibrous tissue. Finally, the rare pleomorphic
rhabdomyosarcomas occur later in life and are characterised
by the presence of haphazardly arranged bizarre cells. Diag-
nosis is often problematic particularly for poorly
differentiated embryonal tumours which can be difficult to
distinguish from other classes of paediatric round cell
tumours, such as neuroblastoma, hepatoblastoma and non-
Hodgkin's lymphoma (Enzinger & Weiss, 1988). The final
tissue diagnosis frequently requires the use of supplementary
techniques such as electron microscopy and, in particular, the
use ofimmunohistochemical reagents which detect, for exam-
ple, muscle-associated intermediate filaments, contractile pro-
teins and myoglobin. The most commonly used antibodies
are those directed against desmin, myoglobin, fast myosin
and sarcomeric actin. Their interpretation is sometimes
difficult particularly in poorly differentiated rhabdomyosar-
comas where expression of muscle-associated proteins is
limited (Schmidt et al., 1988; Carter et al., 1989; Dodd et al.,
1989; Carter et al., 1990). In order to determine whether the
muscle determining genes myf3, myf4, myf5 and myf6 can be
used to assist in the diagnosis of rhabdomyosarcoma we
have, in the present study, examined the expression of these
genes in a series of rhabdomyosarcomas that included
representatives from all three histological categories.
Materials and methods
Tumours and cell lines
Fresh specimens of primary soft tissue sarcomas were
obtained from the Royal Marsden Hospital, London and
Surrey, St Thomas' Hospital, London and The Hospital for
Sick Children, Bristol, and stored at - 70°C. The cell lines
RD, A204, A673 and Hs729 were obtained from the American
Type Culture Collection and maintained under conditions
recommended by the supplier. The RMS cell line (Garvin et
al., 1986) was kindly provided by Dr Julian Garvin.
Preparation ofRNA
Total cellular RNA was prepared from cell lines as described
by Feramisco et al. (1982). To prepare RNA from tumour
material the tumour (up to 0.1 g) was frozen in liquid nitro-
gen and ground into a powder with a pestle and mortar. The
powder was added to 0.3 ml lysis solution (140 mm NaC12,
2 mm MgCl2, 200 mm Tris-HCI, pH 8.5, 0.5%, v/v, Nonidet
P40) containing 1.3 ;g ml-' of the RNAase inhibitor
Aluminon (Aldrich). The mixture was immediately vortexed
for 5 s then centrifuged for 30 s at 8,000g. The supernatant
was recovered and mixed with 0.5 ml of phenol and 0.35 ml
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classes of other paediatric tumours (neuroblastoma, Wilms'
tumour, hepatoblastoma and non-Hodgkin's lymphoma) and
of other soft tissue tumours (leiomyosarcomas). Fifteen
rhabdomyosarcomas had an embryonal histology and were
predominantly from children under 15. Of the remaining five
rhabdomyosarcomas, three had an alveolar histology while
there were single cases ofpleomorphic and mixed embryonal/
alveolar tumours.
To detect transcription of myf genes in primary rhabdo-
myosarcomas Northern blots of total cellular RNA were
hybridised to 32P-labelled cDNA probes. In these experiments
(Figure 1 and Table I) a 2.0 kb myf3 transcript was detected
in 17/20 tumours, a 1.8 kb myf4 transcript was detected in
15/20 tumours, and a 1.7 kb myf5 transcript was found in
11/20 tumours. Transcription of myf6 was observed in 5/18
tumours but there were several different mRNA sizes (1.1,
1.5, 2.2 and 3.5 kb) and some tumours expressed more than
one transcript. Thus STS259 contained both 1.5 and 3.5 kb
transcripts while STS238 contained transcripts of 1.1, 1.5 and
2.2 kb (results not shown). Comparisons of the results
obtained with the four myfprobes failed to reveal consistent
patterns of expression (Table I). Some rhabdomyosarcomas
expressed all four myf genes. Other groups of tumours exp-
ressed (a) myf3, myf4 and myf5 but not myf6 (b) only myf3
and myf4 (c) only myf4 and myfS and (d) only myf3 and
myf5. Finally two tumours, one embryonal rhabdo-
myosarcoma (STS249), and one pleomorphic tumour (STS23)
showed no evidence for transcription of myf genes.
Several rhabdomyosarcoma cell lines were also examined
for expression of the four myf genes. RNA from two lines,
RD and RMS contained abundant myf3 and myf4 tran-
scripts but failed to hybridise to myf5 and myf6 probes
(Figure 1). In contrast for the remaining three lines, A204,
of TSE (0.5%, w/v, SDS, 5 mM EDTA, 10mM Tris HCI,
pH 8.5) vortexed and subject to centrifugation for 1.5 min at
8,000g. The aqueous phase was then extracted twice with
0.5 ml phenol and once with 0.5 ml chloroform. Finally,
following the addition of 2.5 volumes of ethanol, the RNA
was allowed to precipitate at - 20°C for 15 min, pelleted by
centrifugation, redissolved in 40 il of water and stored at
- 200C.
Northern analysis
Northern analysis was performed exactly as described
previously (Stratton et al., 1990) except that the hybridisation
membrane was washed at 650C with 1 x SSC containing
0.5% (w/v) SDS. The following cDNA hybridisation probes
were used: a 0.8 kb EcoRl-EcoRl myf3 fragment (Braun et
al., 1989a); a 1.3 kb EcoRl-EcoRl myf4 fragment (Braun et
al., 1989a); a 1.1 kb BamHl-BamHl myfS fragment (Braun
et al., 1989b); a 1.2 kb EcoRl-EcoRl myf6 fragment (Braun
et al., 1990); and a 1.1 kb PstI-PstI fragment of
glyceraldehyde-3-phosphate dehydrogenase cDNA (kindly
provided by Louise Howe).
Results
Expression ofmyfgenes in human tumours
Fresh tumours biopsies and human tumour cell lines have
been examined for the expression of members of the myf
gene family. The samples examined included 20 primary
rhabdomyosarcomas, five rhabdomyosarcoma cell lines (RD,
RMS, A204, Hs729, A673) and biopsies from representative
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Figure 1 Expression of members of the myf gene family in human rhabdomyosarcomas and in the rhabdomyosarcoma cell lines
RMS, Hs729, RD, A673 and A204 Northern blots of tumour RNA (10 fig per lane) were hybridised sequentially to myf3, myf4,
myfS and myf6 probes. The primary rhabdomyosarcomas examined are designated by their STS numbers (see Table I). Loading of
RNA samples was assessed by staining RNA gels with ethidium bromide and by hybridisation of Northern blots to a
glyceraldehyde-3-phosphate dehydrogenase (G3PD) cDNA probe.
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Table I Expression of markers in human rhabdomyosarcomas
Expression of markersb
Tumour Sex Age Site Typea myf3 myf4 myf5 myf6 Vimentin Desmin Fastmyosin Myoglobin
STS68 F 12 Forearm E + + - - + + -
STS93 M 68 Paratestisc E + - + N.D. + + + +
STS172 M 16 Testisc E + + + + + + + +
STS235 M 18 Perineum E + + - - + + -
STS237 M 8 Retroperitoneum E + - - - + + - +
STS238 M 15 Paratestis E + + + + + + + +
STS239 F 8 Thigh E + + - N.D. + + + +
STS240 F 11 Forearm E + + - - + +
STS246 M 11 Paratestis E + + + - + + - +
STS247 M 6 Bladder E + + + + + + + +
STS248 M 2 Calf E + + + - + + + +
STS249 M 5 Paratestis E - - - - + + - +
STS250 M 5 Bladder E + - - - + + - +
STS251 M 3 Trunk E + + + + + + -
STS261 F 5 Bladder E + - + - + + N.D. N.D.
STS259 F 4 Perianal A + + - + + + N.D.
STS69 F 12 Perineum A + + + - + + N.D. +
STS252 M 23 Unknown A + + + - + + + +
STS253 M 27 Neck A/E - + + - + + N.D. -
STS23 M 57 Buttock P - - - - + + N.D. +
aEmbryonal (E), alveolar (A), or pleomorphic (P); bExpression of myf3, myf4, myf5 and myf6 were determined by Northern
analysis as described in the Materials and methods and illustrated in Figure 1. The presence of vimentin, desmin, fastmyosin and
myoglobin were determined using antibodies as described by Carter et al. (1989, 1990); CThese samples were taken from metastatic
lymph node tumours.
A673 and Hs729 we found no evidence for myfgene expres-
sion. An interesting correlation was observed between the
presence of myf gene transcripts and cell morphology. Thus
the two cell lines (RD and RMS) expressing myf3 and myf4
contained a significant proportion ofspindle shaped cells that
had the appearance of myoblasts while the lines that did not
express members of the myf gene family had an undiffer-
entiated appearance (results not shown). Similar results were
obtained by Hiti et al. (1989) who detected MyoDl (myf3) in
RD cells, but not in A204 and A673 cells, and noticed the
same correlation between MyoDl expression and cell mor-
phology.
To determine whether myf genes are expressed in other
classes of paediatric tumours we have examined three Wilms'
tumours, two neuroblastomas, two hepatoblastomas, and
three non-Hodgkin's lymphomas and, as an additional con-
trol, we analysed two smooth muscle tumours (leiomyosar-
comas). Transcription of myfgenes was not detected in these
tumours (results not shown).
Since each member of the myfgene family contains a short
conserved basic-helix-loop-helix region (Braun et al., 1989a,
1990), the possibility arose that particular myf gene probes
might cross hybridise to transcripts from other family
members. We believe that this is unlikely since, as described
above, comparisons of the levels of transcripts observed with
each of the four myf gene probes revealed many distinct
patterns of hybridisation. In addition, the sizes of several of
the major myf6 transcripts (1.2, 1.4 and 3.5 kb) were quite
distinct from those observed for myf3, myf4 and myf5
(1.7-2.0 kb). It could also be suggested that the signal
resulted from contamination with normal striated muscle.
Again we believe that this is unlikely because (a) care was
taken to remove normal tissue before the samples were stored
(b) many of the tumours were from sites which did not
contain striated muscle and (c) when compared on the same
Northern blot the signal observed for tumour RNA was
usually much more intense than that observed for RNA from
striated muscle (result not shown).
There is some evidence that the expression of myf5 is
correlated with the stage of muscle differentiation. Thus
levels of myf5 transcripts were high in early foetal skeletal
muscle but dropped considerably in adult muscle (Braun et
al., 1989a,b). We were therefore interested to see whether the
level of expression of the myf genes correlated with the
degree of differentiation of rhabdomyosarcomas, which can
be assessed by examining the immunophenotype defined by
antibodies that detect muscle associated epitopes such as
desmin, fast myosin and myoglobin (Carter et al., 1990).
Myoglobin and fast myosin are usually associated with well
differentiated elements that often reveal morphological
features of differentiation towards striated muscle in conven-
tionally stained sections. By comparison desmin is expressed
in a broader spectrum of rhabdomyosarcomas. Unfor-
tunately for the present fairly small groups ofrhabdomyosar-
comas we failed to find any correlation between myf gene
expression and degree of differentiation as determined by
immunohistochemical analysis (Table I).
Discussion
Northern analysis of tumour RNA has been used to demon-
strate that the myf3 gene is expressed in a high proportion of
primary rhabdomyosarcomas. These results are in agreement
with studies carried out in other laboratories. Using a mouse
MyoDl cDNA probe Hiti et al. (1989) detected transcripts in
four out offive primary embryonal rhabdomyosarcomas, and
two out of three rhabdomyosarcomas growing as explants in
vitro. Similarly in studies on fresh rhabdomyosarcomas
Scrable et al. (1989) detected MyoDl-related transcripts in
five out of five alveolar tumours and eight out of eight
embryonal tumours. We have now extended these analyses to
other members of the myfgene family. Our results show that
myf3 was expressed in the majority of rhabdomyosarcomas
(17/20) usually together with myf4. By comparison the myf5
and myf6 genes, although yielding abundant transcripts in
some rhabdomyosarcomas, were expressed in a lower propor-
tion of tumours: 11/20 for myf5 and 6/18 for myf6.
Members of the myfgene family are apparently expressed
quite infrequently in other classes of tumour. Both Hiti et al.
(1989) and Scrable et al. (1989) failed to detect MyoDl-
related transcripts in other groups of paediatric tumours and
in soft tissue tumours. Furthermore, in the present study we
failed to detect transcription of the four myfgenes in Wilms'
tumour, neuroblastoma, hepatoblastoma, paediatric non-
Hodgkin's lymphoma and leiomysarcoma. Since myf gene
expression appears to be restricted to rhabdomyosarcoma, it
is possible that the expression of these genes may prove
useful in the diagnosis of rhabdomyosarcoma. In this regard
myf3 and myf4, which are both expressed in a high propor-
tion of rhabdomyosarcomas may be particularly useful.
One embryonal tumour (STS249) and one pleomorphic1042 J. CLARK et al.
tumour (STS23) failed to show myf gene expression. How-
ever both tumours expressed desmin and myoglobin (Table I)
and the diagnoses were considered to be sound. It is con-
ceivable that the absence of myfgene expression is simply a
reflection of the insensitivity ofNorthern analysis when com-
pared, for example, to the immunohistochemical methods
that were used to detect desmin and myoglobin. A major
advantage of immunohistochemical methods is that they can
be used to detect expression of proteins in small pieces of
tumour. Indeed, if expression of myf genes is to become
widely accepted as a marker in the diagnosis of rhabdo-
myosarcomas, it will be necessary to produce antibodies for
use in routine immunohistochemical studies which ideally
could be used to examine formalin fixed tissue.
In conclusion we have demonstrated that each member of
the gene family myf3, myf4, myf5 and myf6, is expressed in
rhabdomyosarcomas. In addition, since the great majority of
rhabdomyosarcomas express one or more of these genes and
their expression was not detected in other classes of paedia-
tric tumour, they could prove extremely useful in the diag-
nosis of rhabdomyosarcomas. However, if this method is to
be adapted for routine use in histopathology laboratories,
antibodies that recognise the myf proteins will be required.
Indeed it is probable that the production of these antibodies
should represent a major objective of future studies.
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